Sign up
Pharma Capital

PreveCeutical Medical receives second Aurora cannabis shipment

The pot materials will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research...
1526317178_BHP.jpg
The materials from the shipment will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research

PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) has received the second shipment of dried cannabis materials from major Aurora Cannabis, it told investors.

The pot materials will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research.

As revealed in March, the company, in a major milestone, had received the key permits to allow this material to be imported into Australia by the  cannabis major.

It is being used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh at the University of Queensland.

Preveceutical aims to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.

The advantages of Sol-gels over conventional liquid nasal sprays include reduced dosage requirements, and reduced irritation and other negative side effects.

Shares were unchanged at C$0.29.

Giles_55af4ddca6481.jpg
Why Invest In PreveCeutical Medical Inc? Read More Here

Register here to be notified of future PREV Company articles
View full PREV profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.